← board
ATRA
Atara Biotherapeuticsdistress 7/10 · high distress / dilution risk$7.88-3%today-56% from 52w high
Immunology / Inflammation 1Oncology 1
Lead: EBV+ PTLD · target CD19
Revenue
pre-revenue
Liquidity
$8M
Runway
0.3 yrs
Shares 1y
+28%
Price & events
+57.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
-9.6%
1W
-29.4%
1M
+60.8%
3M
+51.0%
6M
-35.7%
1Y
-24.4%
2Y
-97.5%
5Y
-98.4%
All
Overview
- Market Cap
- $71.00M
- Volume
- 4.07K
- 52 Week Range
- $4.18 – $18.09
- Total Shares
- 9.01M
- Float Shares
- 4.66M
- Short %
- 5.72%
- % Held by Insiders
- 16.92%
- % Held by Institutions
- 52.46%
- RVOL
- 0.05x
- Beta
- 0.09
Pipeline stages · 1 programs
ATA3219CD19
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
Catalyst news & presentations · 10
- third quarter 2026Guided 70%regulatory submissionFiled (NDA/BLA)tabelecleucel · Partner Pierre Fabre intends to resubmit BLA with updated ALLELE Phase 3 data.SEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-09crlTabelecleucel · FDA issued Complete Response Letter for EBVALLO BLA.SEC 8-K
- July 14, 2025regulatory submissionFiled (NDA/BLA)tabelecleucel · Resubmitted BLA to FDA addressing prior CRL manufacturing observations.SEC 8-K
- 2025-05-05fda agreementtabelecleucel · FDA granted Type A meeting to discuss path forward for BLA resubmission.SEC 8-K
- 2025-05-05clinical holdtabelecleucel · Clinical hold lifted on active IND applications for EBVALLO program.SEC 8-K
- 2025-01-21clinical holdEBVALLO (tabelecleucel) · FDA placed clinical hold on EBVALLO IND due to GMP compliance issues at third-party manufacturer.SEC 8-K
- 2025-01-21clinical holdATA3219 · FDA placed clinical hold on ATA3219 IND due to same manufacturing issues affecting starting materials.SEC 8-K
- 2025-01-16crltabelecleucel · Complete Response Letter received for EBVALLO BLA due to GMP compliance issues.SEC 8-K
- January 15, 2025PDUFAPDUFAtabelecleucel (tab-cel) · PDUFA target action date for BLASEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $14 (+73% upside) · 3 analysts
- 2026-05-18Freedom BrokerSell → Hold
- 2026-05-08Canaccord GenuityHold → Buy
- 2026-01-21Freedom BrokerBuy → Sell
- 2026-01-13Canaccord GenuityBuy → Hold
- 2025-12-19Canaccord GenuityBuy
- 2025-03-11Canaccord GenuityBuy
Competitors — CD19
Recent news
- 2026-07-22Price to sales forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
- 2026-07-20Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
- 2026-07-20Price to sales forward of Atara Biotherapeutics Inc – TRADEGATE:AT20 - TradingView
- 2026-07-19Enterprise value to EBITDA forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
- 2026-07-16Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewi - The National Law Review
- 2026-07-142026-07-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
- 2026-07-12Enterprise value to revenue forward of Atara Biotherapeutics Inc – MUN:AT20 - TradingView
- 2026-07-12Avoiding Lag: Real-Time Signals in (ATRA) Movement - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.